Somatostatin receptor expression and biological functions in endocrine pancreatic cells: Review based on a doctoral thesis

Upsala Journal of Medical Sciences

Volumn 112, Issue 1, 2007, Pages 1-20

  Ludvigsen, Eva ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOSTATIN RECEPTOR;

ANIMAL; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PANCREAS; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 1; MICE; MICE, INBRED NOD; PANCREAS; RATS; RECEPTORS, SOMATOSTATIN;

EID: 48949103699     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/2000-1967-091     Document Type: Review

References (76)

1. Jansson L and Hellerstrom C (1981). A rapid method of visualizing the pancreatic islets for studies of islet capillary blood flow using non-radioactive microspheres. Acta Physiol Scand 113:371-374.
2. Hellman B (1959). The numerical distribution of the islets of Langerhans at different ages of the rat. Acta Endocrinol (Copenh) 32:63-77.
3. Wierup N, Svensson H, Mulder H, Sundler F (2002). The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regulatory Peptides 107:63-69.
4. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973). Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77-79.
5. Patel Y C (1999). Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198.
6. Moller L N, Stidsen C E, Hartmann B, Holst J J (2003). Somatostatin receptors. Biochim Biophys Acta 1616:1-84.
7. Patel Y C, Greenwood M T, Panetta R, Demchyshyn L, Niznik H, Srikant C B (1995). The somatostatin receptor family. Life Sci 57:1249-1265.
8. Reichlin S (1983). Somatostatin. N Engl J Med 309:1495-1501.
9. Koerker D J, RuchW, Chideckel E, Palmer J, Goodner C J, Ensinck J, Gale C C (1974). Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 184:482-484.
10. Doyle M E and Egan J M (2003). Pharmacological agents that directly modulate insulin secretion. Pharmacological Reviews 55:105-131.
11. Itoh M, Mandarino L, Gerich J E (1980). Antisomatostatin gamma globulin augments secretion of both insulin and glucagon in vitro: evidence for a physiologic role for endogenous somatostatin in the regulation of pancreatic A- and B-cell function. Diabetes 29:693-696.
12. Jansson L and Hellerstrom C (1983). Stimulation by glucose of the blood flow to the pancreatic islets of the rat. Diabetologia 25:45-50.
13. Brunicardi F C, Stagner J, Bonner-Weir S, Wayland H, Kleinman R, Livingston E, Guth P, Menger M, McCuskey R, Intaglietta M, Charles A, Ashley S, Cheung A, Ipp E, Gilman S, Howard T, Passaro E Jr (1996). Microcirculation of the islets of Langerhans. Long Beach Veterans Administration Regional Medical Education Center Symposium. Diabetes 45:385-392.
14. Stagner J I and Samols E (1992). The Vascular Order of Islet Cellular Perfusion in the Human Pancreas. Diabetes 41:93-97.
15. Samols E, Stagner J I, Ewart R B L, Marks V (1988). The Order of Islet Microvascular Cellular Perfusion Is B-]A-]D in the Perfused Rat Pancreas. Journal of Clinical Investigation 82:350-353.
16. Samols E and Stagner J I (1990). Islet Somatostatin - Microvascular, Paracrine, and Pulsatile Regulation. Metabolism-Clinical and Experimental 39:55-60.
17. Kleinman R, Ohning G, Wong H, Watt P, Walsh J, Brunicardi F C (1994). Regulatory Role of Intraislet Somatostatin on Insulin-Secretion in the Isolated-Perfused Human Pancreas. Pancreas 9:172-178.
18. Carlsson P O and Jansson L (1994). The long-acting somatostatin analogue octreotide decreases pancreatic islet blood flow in rats. Pancreas 9:361-364.
19. Yamada Y, Post S R, Wang K, Tager H S, Bell G I, Seino S (1992). Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 89:251-255.
20. Yamada Y, Reisine T, Law S F, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell G I, Seino S (1992). Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 6:2136-2142.
21. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H, Seino S (1993). Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 195:844-852.
22. Florio T and Schettini G (1996). Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors. J Mol Endocrinol 17:89-100.
23. Cristiani R, Petrucci C, Dal Monte M, Bagnoli P (2002). Somatostatin (SRIF) and SRIF receptors in the mouse retina. Brain Res 936:1-14.
24. Fehlmann D, Langenegger D, Schuepbach E, Siehler S, Feuerbach D, Hoyer D (2000). Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery. J Physiol Paris 94:265-281.
25. Raulf F, Perez J, Hoyer D, Bruns C (1994). Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. Digestion 55 Suppl 3:46-53.
26. Hunyady B, Hipkin R W, Schonbrunn A, Mezey E (1997). Immunohistochemical localization of somatostatin receptor sst2A in the rat pancreas (vol 138, pg 2632, 1997). Endocrinology 138:3064-&.
27. Kimura N, Schindler M, Kasai N, Kimura I (2001). Immunohistochemical localization of somatostatin receptor type 2A in rat and human tissues. Endocr J 48:95-102.
28. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel S C, Patel Y C (1999). Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48:77-85.
29. Portela-Gomes G M, Stridsberg M, Grimelius L, Oberg K, Janson E T (2000). Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Molecul Morphol 8:126-132.
30. Mitra S W, Mezey E, Hunyady B, Chamberlain L, Hayes E, Foor F, Wang Y N, Schonbrunn A, Schaeffer J M (1999). Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology 140:3790-3796.
31. Strowski M Z, Parmar R M, Blake A D, Schaeffer J M (2000). Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141:111-117.
32. Strowski M Z, Kohler M, Chen H Y, Trumbauer M E, Li Z H, Szalkowski D, Gopal-Truter S, Fisher J K, Schaeffer J M, Blake A D, Zhang B B, Wilkinson H A (2003). Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Molecular Endocrinology 17:93-106.
33. Cejvan K, Coy D H, Efendic S (2003). Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes 52:1176-1181.
34. Fagan S P, Azizzadeh A, Moldovan S, Ray M K, Adrian T E, Ding X, Coy D H, Brunicardi F C (1998). Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse. Surgery 124:254-258.
35. Patel Y C and Srikant C B (1994). Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 135:2814-2817.
36. Reisine T and Bell G I (1995). Molecular biology of somatostatin receptors. Endocr Rev 16:427-442.
37. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher T J, Pless (1982). SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133-1140.
38. Janson E T and Oberg K (1999). Somatostatin receptor ligands and their use in the treatment of endocrine disorders. Curr Pharm Des 5:693-705.
39. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y (1994). Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93:1321-1325.
40. Lamberts S W J, vanderLely A J, deHerder W W, Hofland L J (1996). Drug therapy - Octreotide. New England Journal of Medicine 334:246-254.
41. Oberg K (1999). Neuroendocrine gastrointestinal tumors - a condensed overview of diagnosis and treatment. Ann Oncol 10 Suppl 2:S3-S8.
42. Cattaneo M G, Taylor J E, Culler M D, Nisoli E, Vicentini L M (2000). Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett 481:271-276.
43. Ludvigsen E, Stridsberg M, Taylor J E, Culler M D, Oberg K, Janson E T (2004). Subtype selective interactions of somatostatin and somatostatin analogs with sst(1), sst(2), and sst(5) in BON-1 cells. Medical Oncology 21:285-295.
44. Zatelli M C, Tagliati F, Taylor J E, Piccin D, Culler M D, degli Uberti E C (2002). Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm Metab Res 34:229-233.
45. Rocheville M, Lange D C, Kumar U, Sasi R, Patel R C, Patel Y C (2000). Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275:7862-7869.
46. Rocheville M, Lange D C, Kumar U, Patel S C, Patel R C, Patel Y C (2000). Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154-157.
47. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp H J, Hollt V, Schulz S (2001). Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 276:14027-14036.
48. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002). SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716.
49. Kohner E M (1993). Diabetic retinopathy. BMJ 307:1195-1199.
50. van Hagen P M, Baarsma G S, Mooy C M, Ercoskan E M, ter Averst E, Hofland L J, Lamberts S W, Kuijpers R W (2000). Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 143 Suppl 1:S43-S51.
51. Grant M B, Mames R N, Fitzgerald C, Hazariwala K M, Cooper-DeHoff R, Caballero S, Estes K S (2000). The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23:504-509.
52. Boehm B O, Lang G K, Jehle P M, Feldman B, Lang G E (2001). Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 33:300-306.
53. Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L, Susini C (2000). Signal transduction of somatostatin receptors negatively controlling cell proliferation. Journal of Physiology-Paris 94:205-210.
54. Lustig R H, Hinds P S, Ringwald-Smith K, Christensen R K, Kaste S C, Schreiber R E, Rai S N, Lensing S Y, Wu S J, Xiong X P (2003). Octreotide therapy of pediatric hypothalamic obesity: A double-blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 88:2586-2592.
55. Vondra K, Voborska M, Kvapil M, Weber P, Dvorakova H, Stanicka S, Zamrazil V (2004). Somatostatin: beneficial effects on remission in young adult patients with newly diagnosed diabetes mellitus type 1. Physiol Res 53:115-117.
56. Atkinson M A and Leiter E H (1999). The NOD mouse model of type 1 diabetes: As good as it gets? Nature Medicine 5:601-604.
57. Lampeter E F, Signore A, Gale E A M, Pozzilli P (1989). Lessons from the Nod Mouse for the Pathogenesis and Immunotherapy of Human Type-1 (Insulin-Dependent) Diabetes-Mellitus. Diabetologia 32:703-708.
58. Leiter E H, Prochazka M, Coleman D L (1987). The Nonobese Diabetic (Nod) Mouse. American Journal of Pathology 128:380-383.
59. Tochino Y (1987). The NOD mouse as a model of type I diabetes. Crit Rev Immunol 8:49-81.
60. Ohneda A, Kobayashi T, Nihei J, Tochino Y, Kanaya H, Makino S (1984). Insulin and glucagon in spontaneously diabetic non-obese mice. Diabetologia 27:460-463.
61. Thomas H E and Kay T W H (2000). Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Diabetes-Metabolism Research and Reviews 16:251-261.
62. Delovitch T L and Singh B (1997). The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7:727-738.
63. Suarez-Pinzon W, Rajotte R V, Mosmann T R, Rabinovitch A (1996). Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-gamma during beta-cell destruction. Diabetes 45:1350-1357.
64. Pozzilli P, Signore A, Williams A J, Beales P E (1993). NOD mouse colonies around the world - recent facts and figures. Immunol Today 14:193-196.
65. Sandler S, Andersson A, Eizirik D L, Hellerstrom C, Espevik T, Kulseng B, Thu B, Pipeleers D G, Skjak-Braek G (1997). Assessment of insulin secretion in vitro from microencapsulated fetal porcine islet-like cell clusters and rat, mouse, and human pancreatic islets. Transplantation 63:1712-1718.
66. Stridsberg M, Hellman U, Wilander E, Lundqvist G, Hellsing K, Oberg K (1993). Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 139:329-337.
67. Ludvigsen E, Olsson R, Stridsberg M, Janson E T, Sandler S (2004). Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem 52:391-400.
68. Rossowski W J and Coy D H (1993). Potent Inhibitory Effects of A Type-4 Receptor-Selective Somatostatin Analog on Rat Insulin Release. Biochemical and Biophysical Research Communications 197:366-371.
69. Rossowski W J and Coy D H (1994). Specific-Inhibition of Rat Pancreatic Insulin Or Glucagon-Release by Receptor-Selective Somatostatin Analogs. Biochemical and Biophysical Research Communications 205:341-346.
70. Ludvigsen E, Stridsberg M, Janson E T, Sandler S (2005). Expression of somatostatin receptor subtypes 1-5 in pancreatic islets of normoglycaemic and diabetic NOD mice. Eur J Endocrinol 153:445-454.
71. Eizirik D L, Sandler S, Palmer J P (1993). Repair of pancreatic beta-cells. A relevant phenomenon in early IDDM? Diabetes 42:1383-1391.
72. Afargan M, Janson E T, Gelerman G, Rosenfeld R, Ziv O, Karpov O, Wolf A, Bracha M, Shohat D, Liapakis G, Gilon C, Hoffman A, Stephensky D, Oberg K (2001). Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 142:477-486.
73. Florio T, Yao H, Carey K D, Dillon T J, Stork P J (1999). Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol 13:24-37.
74. Florio T, Thellung S, Arena S, Corsaro A, Bajetto A, Schettini G, Stork P J (2000). Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J Physiol Paris 94:239-250.
75. Ludvigsen E, Stridsberg M, Taylor J, Culler M D, Öberg K, Janson E T, Sandler S (2006). Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues. Regul Pept, In press
76. Shimon I, Taylor J E, Dong J Z, Bitonte R A, Kim S, Morgan B, Coy D H, Culler M D, Melmed S (1997). Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99:789-798.